Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infec...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Jaime E. Ord óñez and Victor M. Huertas Tags: Research Source Type: research